Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation

Table 1

Baseline characteristics, posttransplant outcomes, and clinical characteristics of patients undergoing KTx.

Variables	Total ()	CD52 <260 pg/mL ()	CD52 ≥260 pg/mL ()	value
Baseline and clinical characteristics
Age (years)				<0.05
Sex (female/male)	34 (35.4%)/62 (64.6%)	21 (36.8%)/36 (63.2%)	13 (66.7%)/26 (33.3%)	NS
Indication for transplantation
Glomerulonephritis (, %)	53 (55.2%)	31 (54.4%)	22 (56.4%)	NS
Autoimmune/polycystic disease (, %)	21 (21.9%)	15 (26.3%)	6 (15.4%)	NS
Pyelonephritis (, %)	7 (7.3%)	5 (8.8%)	2 (5.1%)	NS
Diabetic nephropathy (, %)	6 (6.3%)	3 (5.3%)	3 (7.7%)	NS
Hypertensive nephropathy (, %)	1 (1%)	0 (0%)	1 (2.6%)	NS
Other/unknown (, %)	8 (8.3%)	3 (5.3%)	5 (12.8%)	NS
Preoperative dialysis
No dialysis	3 (3.1%)	2 (3.5%)	1 (2.6%)
Hemodialysis (, %)	85 (88.5%)	52 (91.2%)	33 (84.6%)	NS
Peritoneal dialysis (, %)	8 (8.3%)	3 (5.3%)	5 (12.8%)	NS
Duration of dialysis (months)				NS
Number of total HLA mismatch (, %)
≤2	34 (35.4%)	22 (38.6%)	12 (30.8%)	NS
>2	62 (64.6%)	35 (61.4%)	27 (69.2%)	NS
Preoperative plasma level of CD52 (pg/mL)				<0.0001
Cold ischemia time (minutes)				NS
Repeated KTx (, %)	14 (14.6%)	7 (12.3%)	7 (17.9%)	NS
Serum creatinine
Pretransplantation
3 months after transplantation				NS
6 months after transplantation				<0.05
12 months after transplantation				NS
Postoperative factors and outcomes
Acute allograft rejection (, %)	17 (17.7%)	5 (8.8%)	12 (30.8%)	<0.01
Acute tubular necrosis (, %)	3 (3.2%)	2 (3.6%)	1 (2.6%)	NS
Delayed graft function (, %)	20 (20.8%)	6 (10.5%)	14 (35.9%)	<0.01
CMV (re)activation (, %)	13 (13.5%)	8 (14%)	5 (12.8%)	NS
BK virus infection	17 (17.7%)	6 (10.5%)	11 (28.2%)	<0.05
Graft loss (, %)	22 (22.9%)	8 (14%)	14 (35.9%)	<0.01

HLA: human leukocyte antigen; CMV: cytomegalovirus; KTx: kidney transplantation.